CancerDrs

Prostate Cancer clinical trials in Idaho

8 actively recruiting prostate cancer trials at 11 sites across Idaho.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Network

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Idaho:
  • Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
  • Saint Luke's Cancer Institute - Boise — Boise, Idaho
  • Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
  • Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
  • Saint Luke's Cancer Institute - Fruitland — Fruitland, Idaho
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that keeps growing even when the amount of testosterone in the body i…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06470243
Sites in Idaho:
  • Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
  • Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
  • Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
  • Idaho Urologic Institute-Meridian — Meridian, Idaho
  • Saint Alphonsus Cancer Care Center-Nampa — Nampa, Idaho
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing co…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05806515
Sites in Idaho:
  • Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
  • Saint Luke's Cancer Institute - Boise — Boise, Idaho
  • Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
  • Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
  • Walter Knox Memorial Hospital — Emmett, Idaho
View on ClinicalTrials.gov →
Phase 2 Recruiting Federal

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use ola…

Sponsor: VA Office of Research and Development
NCT ID: NCT04038502
Sites in Idaho:
  • Boise VA Medical Center, Boise, ID — Boise, Idaho
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Idaho:
  • Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
  • Saint Luke's Cancer Institute - Boise — Boise, Idaho
  • Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
  • Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
  • Walter Knox Memorial Hospital — Emmett, Idaho
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Idaho:
  • Massive Bio SYNERGY-AI site — Boise, Idaho
View on ClinicalTrials.gov →
NA Recruiting Industry

WATER IV PCa (AS Sub-study)

The WATER IV study is a multicenter, prospective, randomized clinical trial that aims to evaluate the safety and efficacy of Aquablation therapy in men with localized prostate cancer.

Sponsor: PROCEPT BioRobotics
NCT ID: NCT07650448
Sites in Idaho:
  • Mountain View Hospital — Idaho Falls, Idaho
View on ClinicalTrials.gov →
Recruiting Industry

Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix

The study is a prospective, multi-center, single cohort study involving up to 10 urological clinics in the US. After provision of informed consent, up to 20 mL of whole blood will be collected from each subject. The samples will be blinded…

Sponsor: Sequenom, Inc.
NCT ID: NCT07543757
Sites in Idaho:
  • Idaho Urologic Institute — Meridian, Idaho
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-11-09